我们现在有固定的给药剂量、产生一致且可预测的抗凝反应且无需常规监测的新口服抗凝药物。
We now have new oral anticoagulants that can be given in fixed doses, produce a consistent and predictable anticoagulant response and don't require routine coagulation monitoring.
本研究旨在针对触发和非触发人群,当终止口服抗凝药物治疗后,探究如何识别VTE复发的最强预测因子。
We aimed to identify the strongest predictors of VTE recurrence after discontinuation of oral anticoagulant therapy in a population of both provoked and unprovoked patients.
对于伴有主动脉弓活动性血栓的不明原因卒中患者,建议或者口服抗凝,或者服用抗血小板药物(2c级)。
For patients with cryptogenic stroke associated with mobile aortic arch thrombi, we suggest either oral anticoagulation or antiplatelet agents (Grade 2c).
应用推荐